Parallax Volatility Advisers
STOK icon

Parallax Volatility Advisers’s Stoke Therapeutics STOK Stock Holding History

Parallax Volatility Advisers’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-4,702
Closed -$157K – 3157
2020
Q3 		$157K Buy
+4,702
New +$134K ﹤0.01% 2607

Other funds holding STOK

ALSV
ATP Life Science Ventures New York $898M AUM 84.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Parallax Volatility Advisers's STOK Position: Q4 2020 in Review

Parallax Volatility Advisers sold out of Stoke Therapeutics (STOK) in Q4 2020, closing a stake of 4,702 shares — an estimated $157K sold.

Parallax Volatility Advisers first reported a position in STOK in Q3 2020 and held it in 1 quarter. The position peaked at $157K in Q3 2020. 93 funds tracked by Wall St. Rank hold STOK as of Q4 2020.

  • Parallax Volatility Advisers reported no remaining Stoke Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Parallax Volatility Advisers sold 4,702 Stoke Therapeutics shares in Q4 2020, an estimated $157K.
  • Parallax Volatility Advisers first reported a position in Stoke Therapeutics in Q3 2020 and held it in 1 quarter.
  • Parallax Volatility Advisers's Stoke Therapeutics position peaked at $157K in Q3 2020.
  • 93 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q4 2020.

Based on Parallax Volatility Advisers's 13F filing for Q4 2020, filed 16 Feb 2021.